14.04.2016 • NewsDede WillamsoncologyMerck

Maya Martinez-Davis to Head Oncology at Merck KGaA

With immediate effect, Merck KGaA has appointed Maya Martinez-Davis (46) as global head of oncology for its biopharma business, succeeding Andrew Schiermeier. She will be based in Billerica, Massachusetts, USA, and report to Rehan Verjee, chief marketing and strategy officer of Merck’s Healthcare business.

The new appointee’s responsibilities will include defining integrated global oncology strategies and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck and currently managed under a strategic alliance with Pfizer

Before joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade and prior to that held senior-level and director-level positions with Aventis Pharma in oncology.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.